Literature DB >> 26474316

MDS clinical diagnostic criteria for Parkinson's disease.

Ronald B Postuma1, Daniela Berg2, Matthew Stern3, Werner Poewe4, C Warren Olanow5, Wolfgang Oertel6, José Obeso7, Kenneth Marek8, Irene Litvan9, Anthony E Lang10, Glenda Halliday11, Christopher G Goetz12, Thomas Gasser2, Bruno Dubois13, Piu Chan14, Bastiaan R Bloem15, Charles H Adler16, Günther Deuschl17.   

Abstract

This document presents the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use in clinical research but also may be used to guide clinical diagnosis. The benchmark for these criteria is expert clinical diagnosis; the criteria aim to systematize the diagnostic process, to make it reproducible across centers and applicable by clinicians with less expertise in PD diagnosis. Although motor abnormalities remain central, increasing recognition has been given to nonmotor manifestations; these are incorporated into both the current criteria and particularly into separate criteria for prodromal PD. Similar to previous criteria, the Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity. Explicit instructions for defining these cardinal features are included. After documentation of parkinsonism, determination of PD as the cause of parkinsonism relies on three categories of diagnostic features: absolute exclusion criteria (which rule out PD), red flags (which must be counterbalanced by additional supportive criteria to allow diagnosis of PD), and supportive criteria (positive features that increase confidence of the PD diagnosis). Two levels of certainty are delineated: clinically established PD (maximizing specificity at the expense of reduced sensitivity) and probable PD (which balances sensitivity and specificity). The Movement Disorder Society criteria retain elements proven valuable in previous criteria and omit aspects that are no longer justified, thereby encapsulating diagnosis according to current knowledge. As understanding of PD expands, the Movement Disorder Society criteria will need continuous revision to accommodate these advances.
© 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; absolute exclusion criteria; clinical diagnostic criteria; motor parkinsonism; non-motor manifestations; red flags; supportive criteria

Mesh:

Year:  2015        PMID: 26474316     DOI: 10.1002/mds.26424

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  1205 in total

Review 1.  Mild cognitive impairment in Parkinson's disease.

Authors:  Saul Martinez-Horta; Jaime Kulisevsky
Journal:  J Neural Transm (Vienna)       Date:  2019-04-08       Impact factor: 3.575

2.  Phosphorylated α-synuclein in the retina is a biomarker of Parkinson's disease pathology severity.

Authors:  Isabel Ortuño-Lizarán; Thomas G Beach; Geidy E Serrano; Douglas G Walker; Charles H Adler; Nicolás Cuenca
Journal:  Mov Disord       Date:  2018-05-08       Impact factor: 10.338

3.  Signal Alteration of Substantia Nigra on 3.0T Susceptibility-weighted Imaging in Parkinson's Disease and Vascular Parkinsonism.

Authors:  Xue-Jun Zhao; Xi-Yuan Niu; He-Yang You; Min Zhou; Xue-Bing Ji; Ying Liu; Lei Wu; Xiao-Ling Ding
Journal:  Curr Med Sci       Date:  2019-10-14

Review 4.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 5.  Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.

Authors:  Toshihide Ogawa; Shinya Fujii; Keita Kuya; Shin-Ichiro Kitao; Yuki Shinohara; Mana Ishibashi; Yoshio Tanabe
Journal:  Yonago Acta Med       Date:  2018-09-26       Impact factor: 1.641

6.  The relationship between Parkinson's disease symptoms and caregiver quality of life.

Authors:  Richard S Henry; Sarah K Lageman; Paul B Perrin
Journal:  Rehabil Psychol       Date:  2020-02-17

7.  White Matter Lesions in Mild Cognitive Impairment and Idiopathic Parkinson's Disease: Multimodal Advanced MRI and Cognitive Associations.

Authors:  Swati Rane; Julia Owen; Daniel S Hippe; Brenna Cholerton; Cyrus P Zabetian; Tom Montine; Thomas J Grabowski
Journal:  J Neuroimaging       Date:  2020-09-16       Impact factor: 2.486

Review 8.  Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Authors:  Carlos Estevez-Fraga; Paul Zeun; Jose Luis López-Sendón Moreno
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

9.  Genetic Analysis of Prosaposin, the Lysosomal Storage Disorder Gene in Parkinson's Disease.

Authors:  Yong-Ping Chen; Xiao-Jing Gu; Ru-Wei Ou; Ling-Yu Zhang; Yan-Bing Hou; Kun-Cheng Liu; Bei Cao; Qian-Qian Wei; Wei Song; Bi Zhao; Ying Wu; Jing-Qiu Cheng; Hui-Fang Shang
Journal:  Mol Neurobiol       Date:  2020-11-20       Impact factor: 5.590

10.  Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study.

Authors:  Xia Chen; Qian Zhao; Ji Jiang; Jian Liu; Pei Hu
Journal:  Clin Drug Investig       Date:  2016-05       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.